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Background: Poor adherence to prescribed medication has major consequences. Managing multiple long-term
conditions often involves polypharmacy, potentially increasing complexity and the possibility of poor adherence.
As a result of the globally recognised problems in supporting adherence to medication, some researchers have
proposed the use of reminder charts. The main aim of the research was to explore the need for and perceptions
around the ‘Universal Medication Schedule’ (UMS). Looking at ways in which pharmacists and General Practitioners
(GPs) could use the UMS in NHS settings.
Methods: Semi-structured interviews were carried out with 10 GPs, 10 community pharmacists and 15 patients.
Patients were aged 65 years and over, had multiple long-term conditions and were prescribed at least 5
medications. Interviews were recorded and transcribed and thematic analysis was conducted, using a framework
approach to manage the data.
Results: Attitudes towards the UMS were mixed with stakeholders seeing benefits and limitations to the chart.
Practitioners proposed a number of existing services where they thought the UMS could easily be integrated but
there was evidence of role conflict with GPs feeling it may be best placed with pharmacists and vice versa. The
potential for the UMS to be used as a tool to aid communication between the different services involved in a
patient’s care was a key theme.
Conclusions: The UMS chart provides consolidated medicines information that might help to improve patients’
knowledge and health literacy, which may or may not improve adherence but could help patients in making
informed decisions about their treatment. One of the key benefits of using the UMS in practice is that it could be
introduced across services. In this way it may aid in medicines reconciliation between healthcare settings to ensure
continuity of message, improve patient experience and create more joined up working between services. Further
research is needed to test implementation in different services and to assess outcomes on patient understanding
and adherence.
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Poor adherence to prescribed medication has significant
consequences. It is estimated that 5-8% of hospital admis-
sions in the UK are related to ineffective or inappropriate
use of medicines [1]. A Cochrane review concluded that
improving patients’ use of prescribed medicines may have
a far greater impact on clinical outcomes than an im-
provement in treatments [2]. It has been estimated that
£100 million per annum is wasted on unused prescription
medicines in primary and community care in the UK [3].
Issues related to poor adherence may be particularly im-
portant in patients with multimorbidity. Multimorbidity is
now common among patients with long-term conditions [4]
and many of these patients require multiple medications.
Polypharmacy, the prescribing of multiple medications to
the same individual, increases the risk of adverse drug events
[5,6], and increases the complexity of a regimen and thus
the possibility of non-adherence [7]. Non-adherence may be
intentional or unintentional [8]. Reasons for unintentional
non-adherence may include difficulty opening medicine
containers, lack of understanding of the regimen, or forget-
ting. Underlying reasons for intentional non-adherence will
centre upon patient beliefs about their medicines and condi-
tions. Poor health literacy may also contribute to either form
of non-adherence [9]. It is thought that in the UK between a
half and a third of all medicines prescribed for long-term
conditions are not taken as recommended [10]. Research
has shown that 90% of multi-medication prescriptions can
be dosed four or fewer times a day [11]. However, some re-
search has also shown that without explicit consolidation of
medicines, patients tend to make their regimens more com-
plicated and burdensome than is necessary. In a study con-
ducted in the US, 464 patients were given a hypothetical 7-
drug medication regimen and asked to demonstrate how
and when they would take them, over a 24 hour period, ac-
cording to the information given on the labels. On average
patients identified 6 times (±1.8) in 24 hours to take the 7
medicines. One third dosed the medicines 7 or more times a
day but only 15% stated 4 or fewer times a day (the ideal
dosing schedule) [12].
As a result of the globally recognised problems in sup-
porting patients to correctly adhere to their prescribed
medication, some researchers have worked on the devel-
opment of reminder charts. An early trial conducted in
the UK assessed the impact of a reminder chart on pa-
tients understanding and adherence to medicine regi-
mens on discharge from hospital. The charts were
trialled with 197 patients on discharge from general
medical wards who were prescribed between 2–6 medi-
cines. The results showed that the reminder chart sig-
nificantly improved patients ’ knowledge of their
medicines and also their adherence [13]. In the US, the
‘Universal Medication Schedule’ (UMS) has been devel-
oped [12]. Adherence is a complex and multifactorialissue and there is evidence that simplification of regimen
alone does not solve the adherence problem [10].
Likewise just providing clear instructions/information is
unlikely to improve adherence [14]. The UMS study
aimed to try and address both these issues. The aim was
to standardise prescription labelling and to provide a
simple chart bringing all medicines in a patients’ regi-
men together over 4 dosing periods through the day and
which also explains the purpose of each medication to
improve understanding. The authors report that the
UMS has demonstrated efficacy and effectiveness on
comprehension, consolidation of regimens and improved
adherence measured by pill count [12].
The UMS has been developed for use in the US care
system and has not been evaluated as an intervention on
its own, only in conjunction with simplification of pre-
scription labels. Therefore, it was not clear if the results
would be generalizable, feasible or acceptable to primary
care practice in the UK. The aim of this study was to
examine the perceived need for further support and to
explore GP, pharmacist and patient attitudes towards the
UMS chart and its potential for implementation in pri-
mary care.
Methods
A qualitative study was undertaken in which semi-
structured interviews were carried out with key stakeholders
in patient management of medications. Ten general practi-
tioners, 10 community pharmacists and 15 patients from
the Greater Manchester area took part in interviews. GPs
and pharmacists were recruited by the researcher and with
help from the Greater Manchester Comprehensive Local
Research Network (GMCLRN). After their interview GPs
and pharmacists were each asked to identify up to 5 patients
aged 65 years or over; with a vascular condition comorbid
with at least 1 other long-term condition; and who had been
prescribed at least 5 regular medications. Vascular diseases
were selected to align with the project funder’s priorities
(GM CLAHRC), and because GPs and community pharma-
cists have a primary role in supporting medicines use with
these patients. Practitioners were asked to give information
packs to patients inviting them to take part in an interview.
If interested, patients were advised to return the reply slip
with their contact details in the envelope provided. Patients
were then contacted by the researcher to check eligibility
and to arrange a time and date for the interview.
The patient sample consisted of 8 females and 7 males,
with a mean age of 74.5 years (range 65–89 years).
Patients had a mean of 4.2 conditions (range 2–7) and
were prescribed a mean of 8.7 medicines (range 5–16).
Table 1 shows the individual characteristics of the patients.
The GP sample consisted of 6 males and 4 females from a
range of general practices in Greater Manchester.
Pharmacists were recruited from a range of companies: 4
Table 1 Patient sample characteristics: gender, age, self-report long-term conditions and number of medications
prescribed
ID No. Gender Age (years) Conditions Number of medications
P1 F 67 CHD, Angina, Hypertension, Cholesterol 7
P2 F 81 DM II, Arthritis, Stroke, Depression, hypertension, Glaucoma, underactive thyroid 15
P3 M 81 Angina, COPD 6
P4 M 78 Heart condition, Stroke, Arthritis, blood clot in leg 8
P5 F 66 Heart condition, arthritis 7
P6 M 65 Malignant hypertension, kidney disease, complex regional pain disorder, prolapse disc 14
P7 M 73 Depression, heart attack, arthritis, angina, hypertension 11
P8 M 73 Heart condition, hypertension, cholesterol, severe pain following polio 6
P9 M 74 Ischemic heart disease, hypertension, cholesterol, blind in right eye, cataract left eye 6
P10 F 82 TIA, Angina, COPD, DM II, cellulitis, hypertension 11
P11 F 82 Osteoporosis, heart condition, arthritis, COPD 16
P12 F 66 TIA, hypertension, COPD, cholesterol 5
P13 F 71 Angina, hypertension, arthritis, asthma 8
P14 M 89 CHD, COPD, osteoporosis, angioneurotic oedema 6
P15 M 69 Heart attack, DM II, hypertension, cholesterol 5
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multiples (>50 sites), 3 from regional groups (>10 sites)
and 1 independent pharmacy.
Practitioner interviews focussed on exploring their
thoughts on patient understanding and adherence to their
medication, barriers to - and the importance of - good un-
derstanding as it related to both unintentional and
intentional non-adherence. The interviews also explored
views on current practices and services to help under-
standing and adherence, and their views on the UMS (see
Table 2 for the example chart) including contents/format
of the chart, which patients it could be useful for, how it
might be linked into current practice, and any barriers or
limitations they foresaw in its implementation (See
Additional file 1- practitioner interview schedule).
Prior to interview, written informed consent for participa-
tion in the study was obtained from all participants. Before
the interview with patients, their knowledge and adherence
to their prescribed medication was explored. All patients
were interviewed in their own homes and were asked to pro-
duce all the prescribed and over-the-counter medication theyTable 2 Example Universal Medication Schedule (UMS) chart
Name of medicine Breakfast Lunchtime Even
Amlodipine 5 mg 1 tablet
Lisinopril 10 mg 1 tablet
Simvastatin 20 mg
Metformin 500 mg 1 tablet 1 tab
Paracetamol 2 tablets, if needed 2 tablets, if needed 2 tabcurrently had, whether they were taking it or not. They were
then asked about each medicine individually to see if they
knew what they were taking it for, and asked to describe
exactly when and how they took them. Details were taken
from the prescription labels by the interviewer as a compari-
son. Patient interviews focussed around exploring their expe-
riences of managing multiple medications and any problems
they encountered, where they get their information about
their medication, and experiences of current services (See
Additional file 2- patient interview schedule). Patients were
then shown the example UMS chart (Table 2) and asked if
they thought it would be useful to them, what they thought
it should include, who they thought it should come from
(GP or pharmacist) and any concerns they might have.
All interviews were conducted by the author (CK) and
audio-recorded with consent and fully transcribed.
Interviews lasted between 32 and 63 min (mean 44 min) for
practitioners and between 12 and 66 min (mean 42 min) for
patients. Analysis was conducted according to the constant
comparative method [15], whereby analysis was carried out
concurrently with data collection so that emerging issuesing Meal Bedtime Special instructions
For blood pressure
For blood pressure
1 tablet To reduce cholesterol Do not
drink grapefruit juice
let For diabetes Take with meals
lets, if needed 2 tablets, if needed For pain. Take if needed, not
more than 8 in a day
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themes was inductive. Transcripts were analysed independ-
ently and coded by hand; emerging themes were discussed
until consensus was achieved, and a coding framework that
included higher level themes and relevant data was assem-
bled in Microsoft Word. Each transcript was analysed indi-
vidually and then in groups , with the healthcare
professional transcripts analysed separately from the patient
transcripts but with comparisons made across datasets.
Analysis was conducted by the main author and a sample
of 10% were also coded by other team members. All team
members reviewed the themes with extracted quotes to en-
sure agreement of themes and coding of data. Quotes are
used to illustrate key themes. (Participant codes: GP = GP,
Ph = pharmacist, P = patient).
Ethical approval was granted by NRES Committee
West Midlands- Solihull (13/WM/0125).
Results
Firstly, we looked at the perceived need for further sup-
port for these patients in terms of improving knowledge
and rectifying errors or poor adherence. We also dis-
cussed perceptions around existing services and their
ability to support these patients.
The need for support in medication adherence
Using the information collected on patient knowledge and
adherence to their prescribed medication, we explored the
need for further support for these patients. Patient under-
standing of their medication was mixed, with patients dem-
onstrating some broad knowledge about their medications,
for example, the anti-angina medicine nicorandil was de-
scribed as “for the heart” (P5) when it would have been more
accurate to state that it was for treatment of angina.
However, 11 out of the 15 patients did not know what at
least one of their medications was for. Two patients used a
community monitored dosage system (dosette) both of
whom reported not knowing what the majority of their
medication was for. Two patients had misunderstood what
at least one of their medications was for (for example, the
cholesterol-lowering medicine atorvastatin described as a
“blood thinner” P4).
Nearly all patients reported good adherence to their medi-
cation, but when asked for specific details about how and
when they took each medicine, discrepancies were noted.
Three patients were not taking their medicines as described
on the prescription labels, with a total of 5 medications be-
ing taken incorrectly. For example patient P10 had been pre-
scribed the diabetic medicine metformin ‘1 tablet 3 times a
day’ but was actually taking 1 tablet at breakfast and 1 at
night. Four patients were choosing not to take some of their
medications, or taking it sporadically (without informing
their GP) and still collecting it on repeat prescription (P2
was being prescribed the nutritional supplement Adcal D3™and the painkiller tramadol but had not taken them for the
last 3 years). Only 3 of the 15 patients admitted to forgetting
to take their medications, but during the interview nearly all
patients recalled incidents where they had forgotten to take
some doses and having to take it at a later time when they
remembered. In summary, the majority of wrong medicine
taking was unintentional with only 4/15 patients reporting
intentional non-adherence that had not been discussed with
either a GP or pharmacist.
The interviews explored GP and pharmacist perceptions
on how well patients manage their medication regimens.
Most practitioners felt that some patients experienced dif-
ficulties with medication management. It was also felt by
most that this would therefore impact on adherence:
Not as many people as I’d like to, understand why
they should take what they take, so I’d say more than
half don’t. And, I think the fact that they don’t then
does make a big difference to their adherence. GP1
I’m well aware that it’s not as clear as you would sort
of assume and there is quite a lot of misinterpretation
around dosing schedules and other things that they
have. Again, I’d have said probably half of those
patients won’t take it correctly, if not more. Ph1
The Universal Medication Schedule (UMS)
To explore views on the UMS, patients and practitioners
were given an example chart (Table 2). The interviews ex-
plored views on: usefulness/usability, how it might be deliv-
ered and feasibility of implementing it in the UK care system.
Attitudes towards UMS
Practitioners generally expressed positive views about
the UMS, with all GPs and most pharmacists thinking
that it could be of benefit to particular patients:
I think the ‘what it’s for’ is a really good idea. Because
I’m forever sending out patients, with their repeat
prescriptions, and I’ll write on what they’re all for. GP2
Three of the pharmacists did not feel that the chart
would add much to current practice. However, these
views may have been affected by their perceptions
around the services they provided themselves:
I don’t think it’s going to be of massive benefit in
terms of that chart there where it’s all laid out, there
are some sort of poorly educated patients, and I don’t
think it would necessarily help all them. I think
looking at that could be a bit over-facing actually. Ph1
Patients also had mixed views on how beneficial the
UMS might be for them. When asked if they thought it
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the simplicity of the chart - preferring having all the in-
formation to hand when taking their medications:
It’s short and sweet and you don’t have to sit and read
through all that [PILs], because I don’t know people
that read it anyway P1
Yeah, it would be, because that way I could just pin it…
well, tape it in the cupboard and as I open the cupboard
I can see it as I’m doing my tablets as well P10
Patients often felt that they understood and managed
their medicines well and therefore did not need further
support such as that provided by the UMS chart:
I know what’s in the box and I know what it’s for. Well,
the information’s there so I know what it’s for, like, you
know…I don’t think it would be any more helpful than
what I’ve got already, to be honest with you. P7
However, as described earlier many patients, even
those who thought they managed their medicines well,
were not taking them exactly as prescribed and were un-
clear on what their medicines were for.
How it could help
The ‘Special Information’ column providing details on
what medications are for and any further instructions
was thought to be particularly helpful for patients:
I think what’s helpful is so they know what they’re
taking these tablets for. So that last column is very
helpful. Very helpful indeed, because not only would
it tell them when to take them, but it would tell them
why they do need to take it. GP4
The majority of GPs thought that improved health literacy
would facilitate discussions with patients about their medica-
tions and therefore help patients make informed decsions:
These special instructions, or what it’s for, that’s the
bit that really matters, because once they know what
it’s for, then they can start to challenge and question,
and say, “well actually you’ve given me this, and you
say it’s for my cholesterol, but I thought my
cholesterol was alright doctor?” GP3
However, this seemed to raise an issue for some GPs
who expressed that improved understanding might not
always be beneficial to adherence:
There’s one danger though, and I think this probably
refers again to my specific community here, somepatients may take the decision as to whether they want to
take a medication or not into their own hands, because
they know that this is for blood pressure, they may say,
well, today I feel really well, I’ve checked my blood
pressure on my home machine today and it was normal,
so I probably don’t need that tablet. GP8
Although this view was only expressed by a couple of
GPs this may have implications for delivery of the UMS.
Practitioners also identified that the UMS could be a useful
tool for communicating between settings so between general
practice, pharmacy, hospital and the patient, with everyone
having access to the same information. One pharmacist who
also worked in a hospital pharmacy stated that:
With my hospital hat on it’s really useful to have a list of
all the medication the patient is on in case they get
admitted and they can take it with them. Because when
we used to do the medicines reconciliation it was a
nightmare, they’d come in with bags and bits and drabs
and stuff and you wouldn’t know what they were on. Ph1
GPs also thought that consistency throughout the ser-
vice was a key issue for patient care:
This will allow consistency of message from us as well
as from the pharmacist, and I think it’s the
consistency that’s probably more important than
anything else. GP3
Patients thought that the UMS would be of use but
were less clear in how it would help them. Unlike the
practitioners interviewed, who did not identify that they
thought it would reduce errors, some patients thought
that it would help them prevent errors:
Oh that would be a good idea that…Because I get that
mixed up sometimes, you know, and I think, oh God,
and then I look through the tablets and think, oh, I’ve
got two of them, oh, I’ve got three of them, so the one
that I’ve put extra I throw away! P10
Some patients thought that the UMS alone would not
be sufficient to help them because it doesn’t act as a re-
minder to take the medication or provide any visual evi-
dence (such as an empty container) that they have taken
their medications that day. However, it was suggested that
if used in conjunction with a self-filled dosette box, it may
improve adherence to medicines. One patient who raised
this used her own self-filled dosette box to illustrate:
But, as I say, just something in print isn’t as good as
the physical thing of having the tablets there [in a
dosette tray] P9
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When asked who they thought should deliver the UMS
to the patient, there was evidence of role conflict. The
majority of GPs thought that in terms of time and prac-
ticalities, it would be best delivered in pharmacies.
Conversely some pharmacists thought the chart would
be best delivered by the GP.
However, most GPs and pharmacists stated that it would
have more impact if delivered by multiple sources:
So hit it home at discharge [from hospital] and then
the GP can do that but so can the pharmacist, we can
all sing off the same message but at different points of
the process, and if somebody’s missed at one there’s a
likelihood to be caught in the net later on. Ph4
Suggestions were made as to how the UMS chart
could be best implemented. There are a number of GP
and pharmacy services already in place in the UK (See
Addit ional f i le 3- The Community Pharmacy
Contractual Framework (CPCF)), with the aim of im-
proving knowledge and supporting medicines adherence
in patients. However, these were not always well per-
ceived. Integrating the UMS into the existing services to
provide enhanced support seemed to be logical, and sug-
gestions were made for linking it to a number of these
services:
GP system
In general practice, consultation time and medicines
reviews are the main vehicle to support medication use
in patients , but limitations with this system were
acknowledged:
Because they often…they’ll have some [medications]
and then get more added and more added and it’s…
you might tell them what the new one is but then it’s
reminding them again of what the older ones were
and it can get…I’m sure it gets very complicated. GP5
Some GPs suggested that a tool which can automatic-
ally add new medicines on to an existing chart could
help support this process:
So, what would be nice, is that something like this
[UMS] sits allied to the GP prescribing element, it
recognises everything that’s on repeat prescription,
you press a button, and out it comes. GP3
Medicine Use Reviews (MUR)
MURs are an incentivised scheme delivered by pharma-
cists. Time pressures and targets to complete the max-
imum number of reviews per year (400) were perceived
to have a negative impact on the value of MURs and ontargeting the right patients. As a result of this, most GPs
stated that they saw little value to MURs and that they
viewed them as ‘tick box’ schemes that rarely raised im-
portant issues:
I think the Medicines Use Reviews were entirely
without purpose and benefit and should have been
not done, and we in fact didn’t even read the stuff the
pharmacist sent us we used to throw it straight in the
bin. GP1
Patients who had been offered a MUR were generally
positive about the service although only 4 had actually
taken part in a review. It was thought by most practi-
tioners that this would be a good place to introduce the
UMS as it would allow time for discussion. However, is-
sues around targeting and the small numbers of patients
receiving these services would remain.
I think talking through it would be quite a good
process, it is quite a good lead into an MUR, to be
quite honest with you, or a medication review with
the doctor…I wouldn’t just have it as a bag stuffer, I
think people sometimes ignore the things that are just
stuffed in the bag. Ph4
Monitored Dosage System (dosettes)
The dosette system provides selected patients with their
medications already divided into daily, timed doses. GPs
and pharmacists reported both benefits and problems
associated with using the MDS/dosette system. Two pa-
tients in the sample were currently using the MDS sys-
tem and both had very poor knowledge of their
medications. However, they both felt that it had im-
proved their adherence to some degree:
I tended to take them all at once rather than splitting
it up. And it’s only because they’ve been split up on
this system [dosette] that I started following that, to
some extent, P3
Dosette boxes do have a list of the medicines included
but would not usually indicate what health conditions
the medicines are for. It was also commented on that
this information was not presented well and would be
difficult for some patients to read. The potential for in-
cluding the chart in the dosette tray was suggested:
Well, very often with the [dosette] pack, you know,
when you lift the lid it has that written inside, doesn’t
it? I must say it’s not very well presented in some of
them. It’s like it’s come off a computer from the 80’s
or something, but at least it’s there. You could
upgrade that. GP7
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UMS throughout the system from secondary care to pri-
mary care creating more consistency and improving pa-
tient care would be the most efficient use of the chart:
What we want, and I think what’s really important for
patients, is that if you have the same system all the
way through, because that’s where confusion comes in
otherwise, you know, different formats? So, it would
be really nice, because we’re always talking about
integrated care these days, and lack of fragmentation
of care, and having a consistent message. Well, this is
one of those examples. It should be adopted right the
way through. GP3
Feasibility of implementing UMS
All practitioners thought that the chart would have to be
linked into existing computer packages and to be self-
populating, otherwise it would place too much strain on
GP or pharmacist time:
Otherwise it won’t get done, you know, there just isn’t
time in consultation to be producing something like
this. So it needs to be, sort of, effortless to produce.
But you could have a C side [to a prescription form]
which you’d produce…you know, you’ve got your B
side on your prescription, and you have a C side
which are printed out like this, yeah GP6
Most practitioners agreed that the paper format was
the most practical with the current population. However,
issues around keeping the document up-to-date and en-
suring a patient is using the correct version are a conse-
quence of using hard copies which become historic soon
after printing:
But they like paper, and the other thing about paper is
that if there’s any question about it, they can pick it
up, they can take it to the hospital with them, they
can show it to their relatives. So, I think paper is the
way forward. But, I guess my concern about paper is,
is it always up to date? GP2
Another possible limitation of using hard copies is that
if a patient had only one copy it is unlikely they would
have it with them all of the time:
Even if you don’t lose your bit of paper, it might be
upstairs when you’re downstairs, and it could be time
for your medication, so it’s not going to be with you
all the time is it? GP3
Thinking about feasibility of delivering the UMS chart
in the future, many practitioners thought that it mayneed to move to a digital format. The point was also
made that as the population ages more people will be
used to electronic devices to support their health care:
I think as people who are like my age, you’re not
going to stop using your smart phone and your
computer just because you get to 65. The current
generation of 65 to 75 year olds probably don’t use
computers much although I do come across patients
that do. In the future, if you’re going to plan




It was felt by both GPs and pharmacists, that many pa-
tients with multimorbidity and polypharmacy need fur-
ther support to help improve their understanding of and
adherence to their medications. Most patients thought
that further information and making the important in-
formation easily accessible, would be beneficial. Most
patients felt that they managed their medication well.
However, all except one patient had aspects of their regi-
men that they did not understand or that they did not
adhere to correctly. Intentional and unintentional non-
adherence was seen.
Although potential limitations were identified, most
practitioners and patients thought that the last column
of the chart (Table 2), which gives clear information on
what the medication is for and any specific directions
(such as take with food), was particularly useful for im-
proving health literacy. Most practitioners thought that
improving health literacy would help support patient
choice. However, a small number of GPs displayed pater-
nalistic tendencies and thought that improved health lit-
eracy might not always be beneficial to adherence. None
of the practitioners mentioned that they thought it
would reduce errors in medicine-taking, although this
was not asked as a specific question.
As well as helping to improve patients’ understanding,
it was also felt by practitioners that the UMS could be
used as an effective tool to aid communication between
the different services involved in a patient’s care and also
as an aid for carers in supporting/managing another per-
son’s medication. Although initially conflicted about who
should deliver the UMS, practitioners presented a num-
ber of existing services where they thought the UMS
could easily be integrated and that it could be used
across services to provide a consistent message to pa-
tients. However, there was evidence of a lack of willing-
ness to take responsibility for including the chart in a
patient’s care, which could potentially be a barrier to
use. With the identification of suitable existing services
the UMS could be incorporated into - and the proviso
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degree - most GPs and pharmacists thought that provid-
ing patients with a UMS chart could be feasible, accept-
able and beneficial to patients.
Previous literature
Our results on patient understanding of their medicines
supports other research which has reported that less than
a quarter of people on multiple drug regimens knew the
names and purposes of all their medicines [12,13,16].
There is little research published on practitioner and pa-
tient views around the introduction of reminder charts for
support in medication adherence. Early research con-
ducted in 1993 in the UK, on the introduction of a re-
minder chart, demonstrated significant results [13] but
has not been taken forward in the UK. The research by
Raynor and colleagues focussed on a different population
to that used in this research. In the Raynor study (1993),
patients may have had single conditions (rates of comor-
bidity were not reported), and they also used a lower
threshold for polypharmacy (maximum of 6 medicines).
In contrast the present research only included patients
with 2 or more long-term conditions who had to be taking
at least 5 medications with no upper limit. We are there-
fore looking at patients with a higher level of complexity
and burden caused by treatment regimens. US research on
the UMS has also shown positive results, but much of the
published literature is focussed around labelling changes
as well as the simplification of medicine regimens in to a
chart. The authors report that the UMS has demonstrated
efficacy and effectiveness on comprehension, consolida-
tion of regimens and improved adherence measured by
pill count [12]. However, the research in the US does not
measure patient or provider acceptability, or the impact of
administering the UMS chart alone, independent of
changes made to labelling instructions. One of the key
perceived benefits to introducing the UMS was that it
could be implemented across healthcare settings. The in-
volvement of multiple services in a patients care has been
shown to carry an increased risk of fragmented care and
frequent failures in communication [17]. The need for less
fragmented, minimally disruptive care for patients with
multiple conditions has been commented on in much of
the recent literature around multimorbidity [18-20]. The
UMS, if introduced to hospital pharmacy, primary care
and community pharmacy could provide a common ve-
hicle and language to ensure that all of these services are
working in a ‘seamless’ way when it comes to prescribing
and explaining medicine regimens to patients.
One issue is whether or not improved knowledge does
equate to good adherence. For those patients in this
sample who were using the MDS system, their know-
ledge of their medication was poor but their adherence
was no worse than patients who did know what themajority of their medication was for. This supports other
research which shows that providing clear instructions
or information does not always result in good adherence
[14]. Simplification of a regimen can be helpful to some
patients [21]. However, simplification alone may not
solve the adherence problem [10]. Horne et al. [10] pro-
posed that complexity is not necessarily the key issue
but how well the treatment fits in with an individual pa-
tients routine, expectations and preferences.
Strengths and limitations
One of the strengths of this research is that it explores the
issue of medication adherence in patients with multimorbid-
ity and polypharmacy, targeting a population with complex
medicines regimens. Another key strength is that by inter-
viewing patients, GPs and pharmacists the research explores
medication adherence from the different perspectives of
those involved in all aspects of medication from prescribing
and monitoring, dispensing and advising, to self-
management in adherence. As with most studies that rely
on volunteers to take part in research, the participants may
not be fully representative of their populations. Some practi-
tioners also stated that they had trouble recruiting those pa-
tients who were particularly poor at adherence to their
medication, although we found evidence of clear adherence
issues in the population that did participate. This research
raised some questions about current provider behaviours
but this was not the focus of the interviews. There is poten-
tially the need for further research on changing prescriber
and provider behaviours to better support medicines use in
patients. This research does not provide evidence as to
whether the UMS will actually improve adherence and a
trial is needed to assess this. However, as previously stated,
other research in this area has shown significant improve-
ment in both health literacy and adherence with the use of
similar tools.
Implications
The UMS may impact on unintentional non-adherence
by simplifying a patients’ medicines regimen, thereby re-
ducing burden, and also in acting as a reminder chart. It
was generally felt that intentional non-adherence is more
difficult to address but it is thought that by increasing a
patients’ knowledge and health literacy, which may not
necessarily improve adherence, then patients can at least
make informed decisions about their medication.
However, not all GPs agreed that this would lead to ap-
propriate decisions by patients. Practitioners held mixed
views, and although a number of factors would need to
be addressed for successful use in primary care, it was
generally thought that implementation of such a chart
could be feasible and potentially beneficial. Many of the
GPs and pharmacists interviewed suggested that the use
of a uniform tool such as the UMS, used throughout a
Kenning et al. BMC Health Services Research  (2015) 15:94 Page 9 of 10patients care, could help reduce fragmentation if the pa-
tient is receiving the same message in the same format
from multiple sources. It was also suggested that the use
of a single tool could help communication and medi-
cines reconciliation between primary and secondary care
and community pharmacy services. However, one major
obstacle to this is the numerous different IT systems
currently in use and the lack of a single patient record.
The design of a digital ‘app’ which patients could access
on their phones, computers or tablets and which could
be accessed and updated by health professionals may be
a future consideration.
Conclusions
One of the key benefits of using the UMS in practice, as
identified by GPs and pharmacists is that it could be in-
troduced across services. In this way it may aid in medi-
cines reconciliation between healthcare settings to
ensure continuity of message and improve patient ex-
perience and create more joined up working between
services. Views around the UMS and its ability to im-
prove adherence were mixed. However, it was felt that it
could be of benefit to particular patients and could be
easily placed within existing services and practices.
Further research is needed to test implementation in







Additional file 1: GP/Pharmacist interview schedule.
Additional file 2: Patient interview schedule.
Additional file 3: The Community Pharmacy Contractual
Framework.
Abbreviations
GM CLAHRC: Greater Manchester Collaboration for Leadership in Applied
Health Research and Care; GMCLRN: Greater Manchester Comprehensive
Local Research Network; GP: General Practitioner; MDS: Monitored Dosage
System or dosette; MUR: Medicines Use Review; NHS: National Health Service
UK; PPI: Patient and Public Involvement in research; PRIMER: Primary Care
Research in Manchester Engagement Resource; UMS: Universal Medication
Schedule.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
PB, DA, JP and NG were study investigators and participated in the design
and conduct of the study, the analysis and manuscript development. CK was
responsible for data collection, analysis and manuscript development. All
authors read and approved the final manuscript.Acknowledgements
The authors would like to acknowledge the input of Ailsa Donnelly and
Angela Ruddock from Manchester PRIMER group (Primary Care Research in
Manchester Engagement Resource) which supports PPI (Patient and Public
Involvement) involvement in research. We would like to thank NIHR Primary
Care Research Network- Northwest for its support in recruiting GPs and
pharmacists.
Funding statement
This work was supported by a ‘Research Capability Funding’ grant from the
NIHR Collaboration for Leadership in Applied Health Research and Care for
Greater Manchester (CLAHRC GM). This article presents independent research
commissioned by the NIHR. The views expressed in this publication are
those of the authors and not necessarily those of the National Health
Service, the NIHR, or the Department of Health. The funders had no role in
the design and conduct of the study; the collection, management, analysis,
and interpretation of the data; and the preparation, review, or approval of
the manuscript.
Author details
1NIHR School for Primary Care Research, Centre for Primary Care, Manchester
Academic Health Science Centre (MAHSC), University of Manchester, 5th
floor, Williamson Building, Oxford Road, M13 9PL Manchester, UK. 2Institute
of Primary Care and Health Sciences, Keele University, Keele, UK.
3Independent Pharmacist Researcher and Director- Green Line Consulting
Ltd, Manchester, UK. 4Centre for Pharmacoepidemiology and Drug Safety
Research, Manchester Pharmacy School, NIHR Greater Manchester Primary
Care Patient Safety Translational Research Centre, University of Manchester,
Manchester, UK. 5NIHR Greater Manchester Primary Care Patient Safety
Translational Research Centre, Centre for Primary Care, Manchester Academic
Health Science Centre (MAHSC), University of Manchester, Manchester, UK.
Received: 8 October 2014 Accepted: 17 February 2015
References
1. Report and Action Plan of the Steering Group on Improving the Use of
Medicines. Improving the use of medicines for better outcomes and
reduced waste: An Action Plan. 2012.
2. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for
enhancing medication adherence. Cochrane Database Syst Rev. 2008;16(2):
CD000011. doi: 10.1002/14651858.CD000011.pub3.
3. Office NA. Prescribing costs in primary care. London: The Stationary Office;
2007.
4. Mercer SW, Gunn J, Bower P, Wyke S, Guthrie B. Managing patients with
mental and physical multimorbidity. BMJ. 2012;345:e5559.
5. Calderón-Larrañaga A, Poblador-Plou B, González-Rubio F, Gimeno-Feliu LA,
Abad-Díez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals and
adverse drug events: are we doing things well? Br J Gen Pract. 2012;62:
e821–6.
6. Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, et al.
Risk factors for hospital admissions associated with adverse drug events.
Pharmacotherapy. 2013;33:827–37.
7. Stack R, Elliott R, Noyce P, Bundy C. A qualitative exploration of multiple
medicines beliefs in co-morbid diabetes and cardio-vascular disease. Diabet
Med. 2008;25:1204–10.
8. Schüz B, Wurm S, Warner L, Ziegelmann J, Schwarzer R, Tesch-Romer C.
Medication beliefs predict medication adherence in older adults with
multiple illnesses. J Psychosom Res. 2011;70:179–87.
9. Lehane E, McCarthy G. Intentional and unintentional medication
non-adherence: a comprehensive framework for clinical research and
practice? A discussion paper. Int J Nurs Stud. 2007;44:1468–77.
10. Horne R, Weinman J, Barber N, Elliott R, Morgan M: Concordance,
adherence and compliance in medicine-taking. Report for the National
Co-ordinating Centre for NHS Service Delivery and Organisation R&D 2005.
http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0007/81394/ES-08-1412-
076.pdf
11. Benner JS, Chapman RH, Petrilla AA, Tang SS, Rosenberg N, Schwartz JS.
Association between prescription burden and medication adherence in
patients initiating anti-hypertensive and lipid-lowering therapy. Am J Health
Syst Pharm. 2009;66:1471–7.
Kenning et al. BMC Health Services Research  (2015) 15:94 Page 10 of 1012. Wolf MS, Curtis LM, Waite K, Bailey SC, Hedlund LA, Davis TC, et al. Helping
patients simplify and safely use complex prescription regimens. Arch Intern
Med. 2011;171:300–5.
13. Raynor DK, Booth TG, Blenkinsopp A. Effects of computer generated
reminder charts on patients’ compliance with drug regimens. BMJ.
1993;306:1158–61.
14. Horne R. Compliance, adherence and concordance. In: Taylor & Francis K,
Harding G, editors. Pharmacy practice. London: Taylor; 2001. p. 165–84.
15. Strauss A, Corbin J. Basics of qualitative research techniques and procedures
for developing grounded theory. 2nd ed. Thousand Oaks, CA: SAGE; 1998.
16. Eagleton JE, Walker FS, Barber ND. An investigation into patient compliance
with hospital discharge medication in a local population. Int J Pharm
Practice. 2003;2:107–10.
17. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an
independent risk factor for adverse drug events in an elderly outpatient
population? Am J Geriatr Pharmacother. 2007;5:31–9.
18. May C, Montori V, Mair F. We need minimally disruptive medicine. BMJ.
2009;339:485–7.
19. Haggerty JL. Ordering the chaos for patients with multimorbidity. BMJ.
2012;345:e5915.
20. Jacobs J, Fisher P. Polypharmacy, multimorbidity and the value of
integrative medicine in public health. Eur J Intern Med. 2013;5:4–7.
21. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between
dose regimens and medical compliance. Clin Ther. 2001;23:1296–310.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
